XM tidak menyediakan perkhidmatan kepada penduduk Amerika Syarikat.

Wall St closes up on revival supported by inflation data, tech stocks



<html xmlns="http://www.w3.org/1999/xhtml"><head><title>US STOCKS-Wall St closes up on revival supported by inflation data, tech stocks</title></head><body>

PCE inflation rises moderately in June

Russell 2000, S&P Small Cap 600 gain for fourth day in five

Deckers, Baker Hughes, Norfolk Southern climb after results

Indexes up on Friday: Dow 1.64%, S&P 1.11%, Nasdaq 1.03%

Indexes this week: Dow up 0.8%, S&P down 0.8%, Nasdaq down 2.1%

Updates with closing prices

By David French

July 26 (Reuters) -Wall Street's major indexes ended higheron Friday as investors flocked back to tech megacaps that had triggered broad sell-offs earlier in the week, and inflation data boosted optimism that the Federal Reserve will soon commence cutting interestrates.

For the S&P 500 .SPX and Nasdaq Composite .IXIC, the advances could not completely recoup the ground lost in the two previous sessions, with both indexes ending the week lower for the second consecutive week.

The Dow Jones Industrial Average .DJI ended in positive territory for the week. Its Friday gains were aided byindustrial conglomerate 3M MMM.N, which jumped 23% toits largest daily percentage gain in decades after it raised the lower end of its annual adjusted profit forecast.

Five membersof the so-called Magnificent Seven rose on Friday, led by Meta Platforms .META.O which climbed 2.7%. The two exceptions were Tesla TSLA.O and Alphabet GOOGL.O, whose lackluster earnings had triggered Wednesday's big market sell-off. They both fell 0.2%, with Alphabet dropping to its lowest close since May 2.

With further Magnificent Seven earnings due next week, the immediate outlook for markets may hinge on what type of results these companies deliver.

"What we get next week from Apple <AAPL.O>, Microsoft <MSFT.O>, Amazon.com <AMZN.O> and Meta is really going to set the tone for whether that rotation continues and, directionally, where the market goes," said Greg Boutle, head of US equity & derivative strategy at BNP Paribas.

The rotation involves moving out ofa set ofhigh-momentum stocks, whose valuations now appear inflated,to underperforming sectors like mid- and small-cap stocks.

This shift seems to have gained momentum in recent weeks, with the small-cap Russell 2000 .RUT and S&P Small Cap 600 .SPCY both advancing to their fourth closing highs of the week.

The Russell 2000 .RUT scored its third straight weekly gain in two months and its best three-week run since August 2022.

These economically sensitive small-caps were supported on Friday by themoderate rise in June U.S. prices, which underlined coolinginflation and potentially positions the Fed to start easing policy in September.

Bets on a 25-basis-point cut at the Fed's September meeting held steady at about 88% after the PCE reading, according to CME's FedWatch. Traders still largely expect two rate cuts by December, LSEG data showed.

"We did see (the stable economic data) as beneficial for that broadening trade," said Adam Hetts, global head of multi-asset at Janus Henderson, noting small-caps had outperformed the S&P 500 by more than 10% over the last month.

The broadening trade has also benefited cyclical sectors of the economy. On Friday, all 11 of the S&P sectors were higher, withIndustrials .SPLRCI and Materials .SPLRCM the leading gainers.

On Friday, the S&P 500 .SPX gained 59.88 points, or 1.11%, at 5,459.10 points, while the Nasdaq Composite .IXIC climbed 176.16 points, or 1.03%, to 17,357.88. The Dow Jones Industrial Average .DJI rose 654.27 points, or 1.64%, to 40,589.34.

For the week, the Dow gained 0.75%, while the S&P 500 declined 0.82% and the Nasdaq dropped 2.08%.

Among stocks boosted by earnings, Deckers Outdoor DECK.N jumped 6.3% afterit raised its annual profit forecast, while oilfield services firm Baker Hughes BKR.O climbed 5.8% afterbeating estimates for second-quarter profit.

Norfolk Southern NSC.N soared 10.9%, its largest one-day percentage gain since March 2020, afterthe rail operator reported second-quarter profit above Wall Street estimates thanks to robust pricing.

Medical device maker Dexcom DXCM.O slumped 40.6% aftercutting its annual revenue forecast.

Volume on U.S. exchanges was 10.92 billion shares, compared with the 11.61 billion average for the full session over the last 20 trading days.



Reporting by Ankika Biswas and Lisa Mattackal in Bengaluru and David French in New York; Editing by Saumyadeb Chakrabarty, Pooja Desai and Richard Chang

</body></html>

Penafian: Entiti XM Group menyediakan perkhidmatan pelaksanaan sahaja dan akses ke Kemudahan Dagangan Atas Talian, yang membolehkan sesorang melihat dan/atau menggunakan kandungan yang ada di dalam atau melalui laman web, tidak bertujuan untuk mengubah atau memperluas, juga tidak mengubah atau mengembangkannya. Akses dan penggunaan tersebut tertakluk kepada: (i) Terma dan Syarat; (ii) Amaran Risiko; dan Penafian Penuh. Oleh itu, kandungan sedemikian disediakan tidak lebih dari sekadar maklumat umum. Terutamanya, perlu diketahui bahawa kandungan Kemudahan Dagangan Atas Talian bukan permintaan, atau tawaran untuk melakukan transaksi dalam pasaran kewangan. Berdagang dalam mana-mana pasaran kewangan melibatkan tahap risiko yang besar terhadap modal anda.

Semua bahan yang diterbitkan di Kemudahan Dagangan Atas Talian kami bertujuan hanya untuk tujuan pendidikan/maklumat dan tidak mengandungi – dan tidak boleh dianggap mengandungi nasihat kewangan, cukai pelaburan atau dagangan dan cadangan, atau rekod harga dagangan kami, atau tawaran, atau permintaan untuk suatu transaksi dalam sebarang instrumen kewangan atau promosi kewangan yang tidak diminta kepada anda.

Sebarang kandungan pihak ketiga serta kandungan yang disediakan oleh XM, seperti pendapat, berita, penyelidikan, analisis, harga, maklumat lain atau pautan ke laman web pihak ketiga yang terdapat dalam laman web ini disediakan berdasarkan "seadanya" sebagai ulasan pasaran umum dan bukanlah nasihat pelaburan. Sesuai dengan apa-apa kandungan yang ditafsir sebagai penyelidikan pelaburan, anda mestilah ambil perhatian dan menerima bahawa kandungan tersebut tidak bertujuan dan tidak sediakan berdasarkan keperluan undang-undang yang direka untuk mempromosikan penyelidikan pelaburan bebas dan oleh itu, ia dianggap sebagai komunikasi pemasaran di bawah peraturan dan undang-undang yang berkaitan. SIla pastikan bahawa anda telah membaca dan memahami Notifikasi mengenai Penyelidikan Pelaburan Bukan Bebas dan Amaran Risiko mengenai maklumat di atas yang boleh diakses di sini.

Amaran Risiko: Modal anda dalam risiko. Produk yang berleveraj mungkin tidak sesuai untuk semua individu. Sila pertimbangkan Pendedahan Risiko kami.